EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Stabilizing Plasmodium falciparum proteins for small molecule drug discovery

Marius Amann iD, Tim Sträßer iD, Oliver Einsle iD, Stefan Günther iD

Protein Science · 2026-06 · 35 (6)

DOI: 10.1002/pro.70614 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Protein Science, online erschienen am 02.05.2026. Verfasst von Marius Amann und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institut für Pharmazeutische Wissenschaften, Albert-Ludwigs-Universität Freiburg, Freiburg i. Br, Germany. Hauptthemen laut MEDLINE: Plasmodium falciparum, Protozoan Proteins, Drug Discovery, Antimalarials. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Early‐stage drug discovery relies on the availability of stable protein for reliable biophysical characterization of ligand binding. However, many Plasmodium falciparum proteins are challenging to produce in heterologous systems, which limits their experimental utility. To address this, we tested whether ProteinMPNN‐guided sequence design could generate stabilized surrogate constructs that retain wild‐type‐like structure and binding thermodynamics. Designs were generated with constraints to maintain conserved and binding‐site residues for three therapeutically relevant targets: Pf BDP1‐BRD, Pf BDP4‐BRD, and Pf K13‐KREP. The resulting constructs showed markedly increased thermal stability. Using Pf BDP1‐BRD as a benchmark, isothermal titration calorimetry confirmed that the stabilized variants retained wild‐type‐like binding thermodynamics with a known ligand. Extending this approach to other targets, a Pf K13‐KREP construct led to an apo structure with a binding pocket closely matching the wild type. For Pf BDP4‐BRD, virtual screening against a previously reported wild‐type crystal structure identified putative binders, while a stabilized surrogate for this otherwise unstable target enabled their experimental validation and the determination of a 1.25 Å co‐crystal structure with a newly identified inhibitor. Our findings demonstrate that computationally stabilized surrogates are practical and effective tools for robust biophysics and structure‐enabled drug discovery against otherwise challenging malaria proteins.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plasmodium falciparumProtozoan ProteinsDrug DiscoveryAntimalarialsSmall Molecule LibrariesProtein StabilityBinding SitesModels, MolecularThermodynamics

Stichwörter der Autor:innen

Plasmodium falciparumProteinMPNNdrug discoveryprotein stabilizationx‐ray crystallography

Substanzen

Protozoan ProteinsAntimalarialsSmall Molecule Libraries

Autor:innen und Institutionen

  • Institut für Pharmazeutische Wissenschaften, Albert-Ludwigs-Universität Freiburg, Freiburg i. Br, Germany.
  • Institut für Biochemie, Albert-Ludwigs-Universität Freiburg, Freiburg i. Br, Germany.

ORCID-Profile: Marius Amann, Tim Sträßer, Oliver Einsle, Stefan Günther

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Amann, M., Sträßer, T., Einsle, O., & Günther, S. (2026). Stabilizing Plasmodium falciparum proteins for small molecule drug discovery. Protein Science, 35(6). https://doi.org/10.1002/pro.70614

Vancouver

Amann M, Sträßer T, Einsle O, Günther S. Stabilizing Plasmodium falciparum proteins for small molecule drug discovery. Protein Science. 2026;35(6). doi:10.1002/pro.70614

BibTeX
@article{Amann2026,
  author = {Amann, Marius and Sträßer, Tim and Einsle, Oliver and Günther, Stefan},
  title = {Stabilizing Plasmodium falciparum proteins for small molecule drug discovery},
  journal = {Protein Science},
  year = {2026},
  volume = {35},
  number = {6},
  doi = {10.1002/pro.70614}
}
Kostenlos starten →